In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Boehringer to further develop DeveloGen's metabolic program

Executive Summary

Boehringer Ingelheim has agreed to further develop and acquire worldwide rights to a set of compounds discovered by DeveloGen AG (primarily metabolic disease drug discovery) for diabetes, obesity, metabolic syndrome (which includes hypertension, hyperglycemia, and other health problems that increase the risk for heart disease and diabetes), and conditions related to insulin resistance.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R+D and Marketing-Licensing

Related Companies